Compare Stocks: IKT, SPTX, ETON, and EYPT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$42.05 -3.7%	$37.95	$14.27 ▼ $50.18	$1.20B	0.86	558,442 shs	584,368 shs
EYPT Eyepoint Pharmaceuticals	$13.05 -0.2%	$13.12	$9.65 ▼ $19.11	$1.13B	1.76	1.64 million shs	2.06 million shs
IKT Inhibikase Therapeutics	$2.45 -0.4%	$2.02	$1.33 ▼ $2.53	$324.80M	0.95	1.00 million shs	580,741 shs
SPTX Seaport Therapeutics	$23.36 +1.5%	$19.95	$14.85 ▼ $24.48	$1.23B	N/A	104,015 shs	103,464 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	-3.71%	-8.25%	+14.86%	+36.44%	+146.63%
EYPT Eyepoint Pharmaceuticals	-0.15%	+11.83%	-11.35%	-2.83%	+27.07%
IKT Inhibikase Therapeutics	-0.41%	+0.41%	+20.10%	+28.95%	+244,999,900.00%
SPTX Seaport Therapeutics	+1.48%	+9.01%	+8.25%	+41.58%	+2,335,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$42.05 -3.7%	$37.95	$14.27 ▼ $50.18	$1.20B	0.86	558,442 shs	584,368 shs
EYPT Eyepoint Pharmaceuticals	$13.05 -0.2%	$13.12	$9.65 ▼ $19.11	$1.13B	1.76	1.64 million shs	2.06 million shs
IKT Inhibikase Therapeutics	$2.45 -0.4%	$2.02	$1.33 ▼ $2.53	$324.80M	0.95	1.00 million shs	580,741 shs
SPTX Seaport Therapeutics	$23.36 +1.5%	$19.95	$14.85 ▼ $24.48	$1.23B	N/A	104,015 shs	103,464 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	-3.71%	-8.25%	+14.86%	+36.44%	+146.63%
EYPT Eyepoint Pharmaceuticals	-0.15%	+11.83%	-11.35%	-2.83%	+27.07%
IKT Inhibikase Therapeutics	-0.41%	+0.41%	+20.10%	+28.95%	+244,999,900.00%
SPTX Seaport Therapeutics	+1.48%	+9.01%	+8.25%	+41.58%	+2,335,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	2.50	Moderate Buy	$54.50	29.61% Upside
EYPT Eyepoint Pharmaceuticals	2.89	Moderate Buy	$44.38	240.04% Upside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	120.41% Upside
SPTX Seaport Therapeutics	2.44	Hold	$38.40	64.38% Upside

Current Analyst Ratings Breakdown

Latest IKT, SPTX, ETON, and EYPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$57.00 ➝ $65.00
8/7/2026	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/6/2026	EYPT Eyepoint Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $55.00
8/6/2026	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $27.00
8/4/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $62.00
7/17/2026	ETON Eton Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	ETON Eton Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$86.93M	13.25	$0.00 per share	8,425.30	$0.98 per share	42.91
EYPT Eyepoint Pharmaceuticals	$31.37M	35.86	N/A	N/A	$1.93 per share	6.76
IKT Inhibikase Therapeutics	$260K	1,244.13	N/A	N/A	$2.30 per share	1.07
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	$7.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$4.60M	-$0.07	N/A	22.02	N/A	-1.70%	-5.68%	-1.49%	8/13/2026 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	N/A
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-41.31%	-38.98%	N/A
SPTX Seaport Therapeutics	-$74.88M	-$10.34	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IKT, SPTX, ETON, and EYPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ETON Eton Pharmaceuticals	$0.13	N/A	N/A	N/A	$27.11 million	N/A
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million
8/3/2026	Q2 2026	SPTX Seaport Therapeutics	-$0.71	-$1.78	-$1.07	-$1.78	N/A	N/A
6/8/2026	Q1 2026	SPTX Seaport Therapeutics	-$10.64	-$10.34	+$0.30	-$10.34	N/A	N/A
5/14/2026	Q1 2026	ETON Eton Pharmaceuticals	$0.10	$0.05	-$0.05	$0.05	$22.31 million	$24.27 million
5/12/2026	Q1 2026	IKT Inhibikase Therapeutics	-$0.10	-$0.10	N/A	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	0.62	1.21	0.88
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
IKT Inhibikase Therapeutics	N/A	30.14	30.14
SPTX Seaport Therapeutics	N/A	18.00	18.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
EYPT Eyepoint Pharmaceuticals	99.41%
IKT Inhibikase Therapeutics	3.81%
SPTX Seaport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	16.49%
EYPT Eyepoint Pharmaceuticals	5.13%
IKT Inhibikase Therapeutics	7.10%
SPTX Seaport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	20	27.39 million	22.88 million	Optionable
EYPT Eyepoint Pharmaceuticals	120	86.21 million	81.79 million	Optionable
IKT Inhibikase Therapeutics	6	132.03 million	122.66 million	N/A
SPTX Seaport Therapeutics	N/A	53.53 million	N/A	N/A

IKT, SPTX, ETON, and EYPT Headlines

Recent News About These Companies

Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation

August 11 at 7:00 PM | seekingalpha.com

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages

August 9 at 4:13 AM | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week High - Time to Buy?

August 6, 2026 | marketbeat.com

HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings

August 6, 2026 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX)

August 6, 2026 | americanbankingnews.com

Seaport Therapeutics (NASDAQ:SPTX) Given Buy Rating at HC Wainwright

August 4, 2026 | marketbeat.com

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

August 3, 2026 | businesswire.com

Q2 Earnings Forecast for SPTX Issued By HC Wainwright

July 20, 2026 | marketbeat.com

Seaport Therapeutics (SPTX) Stock Forecast & Price Target

July 19, 2026 | investing.com

Seaport Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SPTX

July 17, 2026 | benzinga.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Rating Upgraded by HC Wainwright

July 16, 2026 | marketbeat.com

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Consensus Rating of "Hold" from Analysts

July 15, 2026 | marketbeat.com

Insider Buying: Seaport Therapeutics (NASDAQ:SPTX) Director Buys $235,820.00 in Stock

June 25, 2026 | insidertrades.com

Seaport Therapeutics, Inc. (SPTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgoâ„¢ in Healthy Volunteers

June 9, 2026 | businesswire.com

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

June 8, 2026 | businesswire.com

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

June 8, 2026 | businesswire.com

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

June 1, 2026 | businesswire.com

Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price Move

May 5, 2026 | finance.yahoo.com

Seaport Therapeutics Pursues IPO On Positive Trial Results

April 13, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IKT, SPTX, ETON, and EYPT Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

$42.05 -1.62 (-3.71%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$42.24 +0.19 (+0.45%)

As of 05:45 AM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$13.05 -0.02 (-0.15%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$13.08 +0.04 (+0.27%)

As of 05:54 AM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Inhibikase Therapeutics NASDAQ:IKT

$2.45 -0.01 (-0.41%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$2.45 0.00 (0.00%)

As of 05:42 AM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Seaport Therapeutics NASDAQ:SPTX

$23.36 +0.34 (+1.48%)

As of 08/11/2026 04:00 PM Eastern

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, SPTX, ETON, and EYPT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, SPTX, ETON, and EYPT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, SPTX, ETON, and EYPT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IKT, SPTX, ETON, and EYPT Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

Eyepoint Pharmaceuticals NASDAQ:EYPT

Inhibikase Therapeutics NASDAQ:IKT

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, SPTX, ETON, and EYPT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, SPTX, ETON, and EYPT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, SPTX, ETON, and EYPT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IKT, SPTX, ETON, and EYPT Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

Eyepoint Pharmaceuticals NASDAQ:EYPT

Inhibikase Therapeutics NASDAQ:IKT

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools